|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||

*
From the Division of Respirology (Drs. Dancey and Downey) and the Division of Medical Microbiology (Dr. Krajden), Department of Medicine, the Department of Laboratory Medicine and Pathobiology (Dr. Chamberlain), and the Division of Otolaryngology (Dr. Alberti), Department of Surgery, University of Toronto, Ontario, Canada; and the Department of Laboratory Medicine (Dr. Palefsky), University of California, San Francisco, CA.
Current address: Provincial Lab, British Columbia Centre for Disease
Control, Vancouver, British Colombia, Canada.
Correspondence to: Gregory P. Downey, MD, FCCP, EN 10212, The Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4; e-mail: gregory.downey{at}utoronto.ca
Cidofovir, a nucleoside analog antiviral agent, has been used with
moderate success in the treatment of juvenile laryngeal papillomatosis
(JLP) by direct intralesional injection. We report the first case where
IV cidofovir was used successfully to treat
a rare but lethal multicystic lung disease complicating JLP. A
35-year-old woman with a history of JLP requiring multiple laser
ablations of laryngeal papillomata each year presented with hemoptysis
and was found on CT scan to have bilateral, multiple pulmonary nodules
and cysts. The results of BAL fluid analysis demonstrated no evidence
of malignancy, and cultures were negative for fungi and mycobacteria.
Molecular DNA typing of a biopsy specimen obtained from a laryngeal
papilloma confirmed infection with human papilloma virus type
11. She received 12 months of treatment with IV cidofovir
followed by 9 months of combined treatmentwith IV cidofovir and
subcutaneous interferon-
-2A. This therapeutic regime resulted in a
markedly decreased requirement for surgical removal of laryngeal
papillomata, and CT scanning documented the regression of the lesions
in the lung parenchyma that persisted after the discontinuation of
therapy. The results of this case demonstrate that cidofovir may be
used successfully to treat JLP-related lung disease and suggest that
further studies are warranted.
Key Words: cidofovir human papilloma virus interferon juvenile laryngeal papillomatosis
This article has been cited by other articles:
![]() |
G. Hennere, L. Havard, B. Bonan, and P. Prognon Stability of cidofovir in extemporaneously prepared syringes Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 506 - 509. [Full Text] [PDF] |
||||
![]() |
E. De Clercq Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections Clin. Microbiol. Rev., October 1, 2003; 16(4): 569 - 596. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. McNamee, D. Lien, L. Puttagunta, and A. A. Conlan Solitary squamous papillomas of the bronchus: a case report and literature review J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 861 - 863. [Full Text] [PDF] |
||||
![]() |
L. M. Akst, W. Lee, C. Discolo, D. Knott, A. Younes, and P. J. Koltai Stepped-Dose Protocol of Cidofovir Therapy in Recurrent Respiratory Papillomatosis in Children Arch Otolaryngol Head Neck Surg, August 1, 2003; 129(8): 841 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. C. Snell New treatments for viral respiratory tract infections--opportunities and problems J. Antimicrob. Chemother., March 1, 2001; 47(3): 251 - 259. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |